Substrates for peptidase C14.026: paracaspase
Peptide and protein substrates that are thought to be physiologically relevant are indicated by P. Peptide and protein substrates that are thought to be pathologically relevant are indicated by D. Peptide and protein substrates that are not physiologically relevant are indicated by N. Synthetic substrates are indicated by S. Click on the symbol to show only physiological, non-physiological or synthetic substrates, or here to display all substrates. How cleavage sites have been identified are indicated by the following evidence codes: NT = N-terminal sequencing, MS = mass spectroscopy, MU = mutation, CS = consensus sequence, LC = liquid chromatography. To see all annotated cleavages for a protein substrate, click on the UniProt Accession.
| Substrate | Uniprot | Residue range | Cleavage Site | Cleavage type | Evidence | P4 | P3 | P2 | P1 | P1' | P2' | P3' | P4' | Reference | CutDB | MERNUM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ac-Ala-Leu-Val-Ser-Arg-ACC | Ac-Ala-Leu-Val-Ser-Arg+ACC | S | Leu | Arg | Ser | Arg | ACC | - | - | - | Hachmann et al., 2012 | |||||
| Ac-Leu-Arg-Ser-Arg-ACC | Ac-Leu-Arg-Ser-Arg+ACC | S | Leu | Arg | Ser | Arg | ACC | - | - | - | Hachmann et al., 2012 | |||||
| Ac-Leu-Arg-Ser-Arg-AFC | Ac-Leu-Arg-Ser-Arg+AFC | S | Leu | Arg | Ser | Arg | AFC | - | - | - | Hachmann et al., 2012 | |||||
| Ac-Leu-Val-Ser-Arg-ACC | Ac-Leu-Val-Ser-Arg+ACC | S | Leu | Val | Ser | Arg | ACC | - | - | - | Hachmann et al., 2012 | |||||
| B-cell lymphoma/leukemia 10 | Q9Z0H7 | 1-233 | peptide-Arg228+Ala-peptide | P | NT | Leu | Arg | Ser | Arg | Ala | Leu | Ser | Arg | Jaworski et al., 2014 | ||
| B-cell lymphoma/leukemia 10 (Bcl-10) | O95999 | 1-233 | peptide-Arg228+Thr-peptide | P | Leu | Arg | Ser | Arg | Thr | Val | Ser | Arg | Rebeaud et al., 2008 | |||
| caspase recruitment domain-containing protein 10 | Q9BWT7 | 1-1032 | peptide-Arg587+Gly-peptide | P | NT | Leu | Leu | Ala | Arg | Gly | Cys | Gly | Leu | Israel et al., 2021 | ||
| Leu-Arg-Ser-Arg-AMC | Leu-Arg-Ser-Arg+AMC | S | Leu | Arg | Ser | Arg | AMC | - | - | - | Rebeaud et al., 2008 | |||||
| lIM domain and actin-binding protein 1 | Q9UHB6 | 1-759 | peptide-Lys449+Gly-peptide | P | NT | Phe | Lys | Ser | Lys | Gly | Asn | Tyr | Asp | Nie et al., 2015 | ||
| lIM domain and actin-binding protein 1 | Q9UHB6 | 1-759 | peptide-Arg366+Ala-peptide | P | NT | Pro | Asp | Ser | Arg | Ala | Ser | Ser | Leu | Nie et al., 2015 | ||
| Mitogen-activated protein kinase kinase kinase 14 (NIK) | Q99558 | 1-947 | Peptide-Arg325+Gly-Peptide | P | Cys | Leu | Ser | Arg | Gly | Ala | His | Glu | Hachmann et al., 2012 | |||
| mucosa-associated lymphoid tissue lymphoma translocation protein 1 | Q9UDY8 | 1-824 | peptide-Arg149+Ala-peptide | P | MU | Leu | Cys | Cys | Arg | Ala | Thr | Gly | His | Baens et al., 2014 | ||
| mucosa-associated lymphoid tissue lymphoma translocation protein 1 | Q9UDY8 | 2-824 | peptide-Arg781+Thr-peptide | P | NT | His | Cys | Ser | Arg | Thr | Pro | Asp | Ala | Ginster et al., 2017 | ||
| mucosa-associated lymphoid tissue lymphoma translocation protein 1 homolog | Q2TBA3 | 2-832 | peptide-Arg789+Thr-peptide | P | NT | His | Cys | Ser | Arg | Thr | Pro | His | Thr | Ginster et al., 2017 | ||
| nEDD4-binding protein 1 | O75113 | 1-896 | peptide-Arg509+Gly-peptide | P | NT | Phe | Val | Ser | Arg | Gly | Ala | Ser | Ser | Yamasoba et al., 2019 | ||
| ranBP-type and C3HC4-type zinc finger-containing protein 1 | Q9BYM8 | 1-510 | peptide-Arg165+Gly-peptide | P | MS | Leu | Gln | Pro | Arg | Gly | Pro | Leu | Glu | Klein et al., 2015 | ||
| ranBP-type and C3HC4-type zinc finger-containing protein 1 | Q9WUB0 | 1-508 | peptide-Arg165+Gly-peptide | P | MS | Leu | Gln | Ser | Arg | Gly | Pro | Leu | Glu | Elton et al., 2016 | ||
| ribonuclease ZC3H12A (regnase-1) | Q5D1E7 | 1-596 | peptide-Arg111+Gly-peptide | P | NT | Leu | Val | Pro | Arg | Gly | Gly | Ser | Thr | Jeltsch et al., 2014 | ||
| roquin-1 | Q5TC82 | 1-1133 | peptide-Arg510+Gly-peptide | N | MU | Leu | Ile | Pro | Arg | Gly | Thr | Asp | Pro | Jeltsch et al., 2014 | ||
| roquin-1 | Q5TC82 | 1-1133 | peptide-Arg579+Gly-peptide | N | AB | Met | Val | Pro | Arg | Gly | Ser | Gln | Leu | Jeltsch et al., 2014 | ||
| roquin-1 | Q4VGL6 | 1-1130 | peptide-Arg510+Gly-peptide | P | MU | Leu | Ile | Pro | Arg | Gly | Thr | Asp | Pro | Jeltsch et al., 2014 | ||
| roquin-1 | Q4VGL6 | 1-1130 | peptide-Arg579+Gly-peptide | P | MU | Met | Val | Pro | Arg | Gly | Ser | Gln | Leu | Jeltsch et al., 2014 | ||
| roquin-2 | P0C090 | 1-1187 | peptide-Arg509+Gly-peptide | N | NT | Leu | Ile | Pro | Arg | Gly | Thr | Asp | Ser | Jeltsch et al., 2014 | ||
| roquin-2 | Q9HBD1 | 1-1191 | peptide-Arg509+Ser-peptide | P | NT | Leu | Ile | Ser | Arg | Ser | Thr | Asp | Ser | Jeltsch et al., 2014 | ||
| transcription factor RelB | Q01201 | 1-579 | peptide-Arg85+Gly-peptide | P | MU | Leu | Val | Ser | Arg | Gly | Ala | Ala | Ser | Hailfinger et al., 2011 | ||
| transcription factor RelB | Q04863 | 1-558 | peptide-Arg64+Gly-peptide | P | NT | Leu | Val | Pro | Arg | Gly | Pro | Ala | Ser | Hailfinger et al., 2011 | ||
| tumor necrosis factor alpha-induced protein 3 (A20) | P21580 | 1-790 | peptide-Arg439+Gly-peptide | P | Gly | Ala | Ser | Arg | Gly | Glu | Ala | Tyr | Coornaert et al., 2008 | |||
| Ubiquitin carboxyl-terminal hydrolase CYLD | Q9NQC7 | 1-956 | Peptide-Arg324+Gly-Peptide | P | NT | Phe | Met | Ser | Arg | Gly | Val | Gly | Asp | Hachmann et al., 2012 | ||
| ubiquitin carboxyl-terminal hydrolase CYLD | Q80TQ2 | 1-952 | peptide-Arg321+Gly-peptide | P | MS | Phe | Met | Ser | Arg | Gly | Val | Gly | Asp | Klei et al., 2016 | ||
| ubiquitin carboxyl-terminal hydrolase CYLD | Q9NQC7 | 1-956 | peptide-Arg324+Gly-peptide | P | MS | Phe | Met | Ser | Arg | Gly | Val | Gly | Asp | Staal et al., 2011 |
